Abstract: The disclosure provides a composition comprising immunoglobulin from an equine that has been hyper-immunized with a filovirus immunogen. The disclosure further provides methods of making such compositions and methods of using such compositions, e.g., for treating Ebola virus infection.

Abstract: The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.

Abstract: The present disclosure provides antibodies, and antigen-binding fragments thereof that bind to EBOV glycoprotein. The present disclosure further provides hybridoma cell lines and methods for making and using the compositions provided herein.

Abstract: The disclosure provides binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.

Abstract: This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriocin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.

Abstract: The present invention provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the present invention provides methods of inducing an immune response against an alpha-hemolysin-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: The present invention provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the present invention provides methods of inducing an immune response against an alpha-hemolysin-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: Compositions and methods for the treatment or prevention of Staphyloccus aureus infection in a subject are provided. Antibody compositions comprising monoclonal antibodies to alpha-hemolysin protein are also provided. The methods provide administering a composition to the subject in an amount effective to reduce or eliminate or prevent relapse S. aureus bacterial infection and/or induce an immune response to Staphylococcus aureus alpha-hemolysin.

Abstract: The present invention provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the present invention provides methods of inducing an immune response against an alpha-hemolysin-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

Abstract: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.

Abstract: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.